Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lapatinib plus trastuzumab versus trastuzumab plus chemotherapy in HER2-positive refractory metastatic breast cancer
2013-005044-29Phase 2Completed
- Sponsor
- Consorzio Oncotech
- Start
- May 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in HER2-positive breast cancer comparing Tyverb + Herceptin with Herceptin + chemotherapy (2 arms). Primary endpoint: Clinical benefit rate. Started May 2014; status: completed.
02
Drugs
lapatinibtrastuzumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on 2013-005044-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005044-29.